Strattec Security (STRT) 10-K: MD&A Changes Lead 28 August 2026 Filing Roundup

Strattec Security (STRT)’s MD&A section changed the most among 5 companies that filed 10-Ks on 28 August 2026, each compared against its prior-year filing.

Desk:
SEC What Changed — 28 August 2026 10-K filing snapshot
STRT+6.71%
IBIO+70.73%
JKHY+5.48%
KOSS-44.84%

Five companies met our criteria from the five 10-K annual reports filed with the SEC on 28 August 2026. To qualify, a company must have filed an annual 10-K report on the target date and have a prior-year 10-K available for a direct year-over-year comparison.

SEC What Changed Methodology

Each company is scored on how similar its current annual filing text is to the prior year. Scores run from 0 to 1 — a score of 1 means the language is essentially unchanged; a lower score means more has changed. We flag three sections that carry the most disclosure signal: Business, Risk Factors, and MD&A. Recent research suggests that lower scores indicate that a company has made significant changes to their filings, these changes are often buried in the filings. If a company was to report positive news, they would likely do so in the form of a press release or statement on their website. The large changers have often underperformed in the market, while the stable-language filers have earned positive abnormal returns.

Key Takeaways

  • STRATTEC SECURITY CORP (Medium) — STRATTEC is signaling a deliberate margin-and-growth reset, with execution on transformation now the key driver to watch.
  • iBio, Inc. (Medium) — iBio is betting on a new clinical-stage obesity-focused story while writing off IBIO-101, but liquidity remains a key risk.
  • KOSS CORP (Medium) — Koss is telling investors that China concentration and tariff uncertainty remain the key margin risks.
  • REST EZ Inc. (Low) — This filing is mostly housekeeping, but the new cybersecurity disclosure and continued reliance on financing underscore a small, early-stage business with limited operating scale.
  • JACK HENRY & ASSOCIATES INC (Low) — Jack Henry’s filing is largely a roll-forward, but the new faster-payments emphasis and wage inflation risk are the key signals to watch.

Ranking Table

RankCompanyCIKFull Filing SimilarityBusiness SimilarityRisk Factors SimilarityMD&A SimilarityMost Changed SectionAssessment
1STRATTEC SECURITY CORP9330340.9970.9950.9950.965MD&Amedium
2iBio, Inc.14207200.9780.9920.9970.996Businessmedium
3KOSS CORP567010.9970.9950.9940.995Risk Factorsmedium
4REST EZ Inc.17338610.981n/a0.9970.995MD&Alow
5JACK HENRY & ASSOCIATES INC7791520.9980.9990.9990.991MD&Alow

STRATTEC SECURITY CORP

Rank1
Lowest similarity sectionMD&A
Assessmentmedium
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

STRATTEC’s MD&A now frames the company as a broader automotive access platform and emphasizes an ongoing transformation to improve profitability and cash generation. Management is highlighting systems upgrades, automation, and a leaner cost structure while also pushing for more business with existing customers and new wins outside its core base. The update reads more like a multi-year operating reset than a simple year-over-year performance review.

Main Changes

  • The business overview was rewritten from a traditional auto-lock supplier description to a broader "global automotive access company" focused on "Permission," "Motion," and "Hold" solutions across the automotive and mobility industries.
  • Management added a new strategic priority: a "business transformation" aimed at stronger profitability, sustainable sales growth, upgraded systems and processes, modernization of support functions, and better productivity and working capital efficiency.
  • The company now says it will use its engineering base to "capture more content," win new platforms and customers domestically and abroad, and build opportunities in the broader transportation industry.
  • The fiscal 2026 update added specific operating results: net sales up 3% to $579.4 million, gross margin up 150 basis points to 16.5%, net income up 10% to $20.6 million, and operating cash flow of $46.3 million.

Watch Items

  • The transformation language signals management is prioritizing margin improvement and operating discipline, not just volume growth.
  • The push to diversify customers and geography matters because the company still relies heavily on the three largest North American OEMs.
  • Headcount reduction of about 7% and automation/process investments suggest cost savings may support earnings, but execution risk remains.

Important Filing Changes

2025 filing excerpt – MD&A

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management’s Discussion and Analysis should be read in conjunction with the accompanying audited consolidated financial statements and notes. Business Overview Strattec Security Corporation is a leading global manufacturer and provider of highly engineered advanced automotive access and security products and solutions. Products include locks & locksets, vehicle start systems, engineered latches, power access solutions, door handles, keys & fobs and other vehicle access products.

2026 filing excerpt – MD&A

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management’s Discussion and Analysis should be read in conjunction with the accompanying audited consolidated financial statements and notes. Business Overview Strattec is a global automotive access company that designs and delivers safe, secure, and highly engineered access solutions for the automotive and mobility industries. Built on generations of access and security engineering expertise, Strattec partners closely with OEMs to create differentiated, system‑level access experiences for end consumers.

2025 filing excerpt – MD&A

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management’s Discussion and Analysis should be read in conjunction with the accompanying audited consolidated financial statements and notes. Business Overview Strattec Security Corporation is a leading global manufacturer and provider of highly engineered advanced automotive access and security products and solutions. Products include locks & locksets, vehicle start systems, engineered latches, power access solutions, door handles, keys & fobs and other vehicle access products.

2026 filing excerpt – MD&A

Business Overview Strattec is a global automotive access company that designs and delivers safe, secure, and highly engineered access solutions for the automotive and mobility industries. Built on generations of access and security engineering expertise, Strattec partners closely with OEMs to create differentiated, system‑level access experiences for end consumers. Strattec’s portfolio spans the access journey from Permission, enabling secure vehicle entry through advanced mechanical and electronic systems; to Motion, delivering effortless, reliable powered access that enhances everyday usability; and through to Hold, providing precision‑engineered latching solutions that give drivers confidence through proven strength, safety, and durability trusted by OEMs worldwide.

2025 filing excerpt – Business

Exhibits and Financial Statement Schedules 49 ITEM 16. Form 10-K Summary 52 Signatures 53 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS In this Annual Report on Form 10-K for Strattec Security Corporation ("Strattec," "the Company," "we," "us," or "our"), statements that are not reported financial results or other historic information are "forward-looking statements." These forward-looking statements relate to, among other things, the Company’s future financial position, business strategy, targets, projected sales, costs, income, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations. The use of words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "project" or "plan" or similar terminology are generally intended to identify forward-looking statements.

2026 filing excerpt – Business

Exhibits and Financial Statement Schedules 54 ITEM 16. Form 10-K Summary 56 Signatures 57 Schedule II 58 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS In this Annual Report on Form 10-K for Strattec Security Corporation ("Strattec," "the Company," "we," "us," or "our"), statements that are not reported financial results or other historic information are "forward-looking statements." These forward-looking statements relate to, among other things, the Company’s future financial position, business strategy, targets, projected sales, costs, income, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations. The use of words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "project," "plan" or similar terminology are generally intended to identify forward-looking statements.

iBio, Inc.

Rank2
Lowest similarity sectionBusiness
Assessmentmedium
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

iBio has repositioned itself from a preclinical company to a clinical-stage developer focused on precision antibodies for obesity and related cardiometabolic and cardiopulmonary diseases. At the same time, it stopped marketing IBIO-101 and wrote off the remaining value of that asset, showing a sharper pivot in pipeline priorities. The company also continues to flag liquidity pressure and the risk of more asset impairments if market or development assumptions worsen.

Main Changes

  • The company now describes itself as a "clinical-stage" business, versus "preclinical" last year, signaling it has moved its lead programs further along development.
  • Management says it "ceased our marketing efforts of the IBIO-101 asset" and "fully impaired the remaining $2.5 million value" of that asset.
  • The business focus is now explicitly on "hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases," replacing the prior emphasis on IBIO-101.
  • The filing says the company continues to face "liquidity challenges" and may need to adjust cash flow and valuation assumptions, with future impairments possible.

Watch Items

  • The move from preclinical to clinical-stage is a meaningful positioning change and suggests the pipeline is advancing, but investors should look for proof of clinical execution.
  • Dropping IBIO-101 marketing and fully impairing the asset indicates management is reallocating attention and capital away from a prior program.
  • Persistent liquidity pressure and impairment risk raise the bar for financing discipline and near-term operating updates.

Important Filing Changes

2025 filing excerpt – Business

Overview iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop.

2026 filing excerpt – Business

Overview iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop.

2025 filing excerpt – Business

Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed to address unmet needs by current glucagon-like peptide-1 (“GLP-1”) receptor agonists. We believe the future of obesity care lies not just in weight loss—but in quality weight loss.

2026 filing excerpt – Business

Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed at addressing unmet needs by current approved therapies. We believe the future treatment for obesity lies not just in overall weight loss, but in the quality, durability, and tolerability of weight loss.

2025 filing excerpt – MD&A

Unless the context requires otherwise, references in this Report to “iBio,” the “Company,” “we,” “us,” or “our” and similar terms mean iBio, Inc. Overview We are a preclinical stage biotechnology company leveraging the power of AI for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and ML to unveil novel biologics which other scientists have been unable to develop.

2026 filing excerpt – MD&A

Unless the context requires otherwise, references in this Report to “iBio,” the “Company,” “we,” “us,” or “our” and similar terms mean iBio, Inc. Overview We are developing next-generation antibody medicines for obesity and its cardiometabolic and cardiopulmonary complications. One of the most important advances in modern obesity treatment has been the emergence of GLP-1 receptor agonists and other incretin-based therapies.

KOSS CORP

Rank3
Lowest similarity sectionRisk Factors
Assessmentmedium
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

Koss broadened its risk disclosure around international operations, with a sharper focus on China exposure, tariffs, and geopolitical disruption. The company also says it is already seeing higher logistics costs and import duties, while acknowledging it may not be able to fully pass those costs on to customers. Overall, the filing reads as a more explicit warning that supply-chain and trade-policy volatility could weigh on margins.

Main Changes

  • The risk section was reorganized into a new heading, "Risks Related to our International Operations," and now says foreign operations and counterparties expose the company to "political, governmental, and economic instability" plus currency swings.
  • Koss added a more explicit U.S.-China trade warning, saying recent court rulings on IEEPA tariffs "have not eliminated the risk" of higher import duties and that new tariffs may still be imposed under Sections 122, 301 and 232.
  • The filing adds geopolitical detail on Russia and the Middle East, stating those conflicts have increased instability, shipping disruption, energy costs and supply-chain pressure.
  • The manufacturing discussion now says substantially all manufacturing is concentrated in China and Taiwan, with "increased logistics costs and higher import duties" already affecting the business, while also noting management is evaluating alternative sourcing where appropriate.

Watch Items

  • The company is signaling that tariff and trade-policy volatility remains a direct margin risk, especially because it says most manufacturing is still concentrated in China.
  • The added geopolitical language suggests more sensitivity to shipping, freight and input-cost shocks, which could pressure profitability if Koss cannot pass costs through.
  • Management’s mention of alternative sourcing is a modest diversification signal, but the filing still implies limited near-term flexibility in the supply chain.

Important Filing Changes

2025 filing excerpt – Risk Factors

See further discussion below under “ The Company is dependent on the proper functioning of our contract manufacturers, our supply chain, and our distribution networks. Any disruptions could adversely affect our business, financial condition or results of operations ” and “ A shift in U.S. and China trade relations, policies and imposed tariffs could adversely affect the Company’s business, financial condition and results of operations.” Geopolitical tensions, armed conflicts and acts of terrorism could adversely affect our business, financial condition, and results of operations. Ongoing and escalating geopolitical conflicts, including the Russia – Ukraine war, instability in the Middle East, and heightened tensions between the United States and China, create significant uncertainty in the global economic and regulatory environment.

2026 filing excerpt – Risk Factors

Risks associated with potential operations, commitments, and investments outside of the U.S. include but are not limited to risks of:  global and local economic, social and political conditions and uncertainty;  currency exchange restrictions and currency fluctuations;  export and import duties;  additional tariffs imposed on exports from the U.S. to other countries, potentially impacting pricing to customers in those countries;  war, such as the invasion of Ukraine by Russia, military conflicts in the Middle East or terrorist attack;  local outbreak of disease or pandemic;  renegotiation or nullification of existing contracts or international trade arrangements;  labor market conditions and workers’ rights affecting our manufacturing operations or those of our customers;  macro-economic conditions impacting key markets and sources of supply;  changing laws and policies affecting trade, taxation, financial regulation, immigration, and investment;  compliance with laws and regulations that differ among jurisdictions, including those covering taxes, intellectual property ownership and infringement, imports and exports, anti-corruption, and anti-bribery, antitrust and competition, data privacy, and environment, health, and safety; and  general hazards associated with the assertion of sovereignty over areas in which operations are conducted, transactions occur, or counterparties are located. A shift in U.S. and China trade relations, policies and imposed tariffs could adversely affect the Company’s business, financial condition and results of operations. The Company’s operations and financial results are subject to risks arising from evolving U.S.-China trade relations.

2025 filing excerpt – Risk Factors

Any disruptions could adversely affect our business, financial condition or results of operations. The Company relies on our third-party supply chain and distribution networks and the availability of necessary components to produce a considerable number of our products. A reduction or interruption in supply, including interruptions due to possible future pandemic- related restrictions, geopolitical unrest, labor shortages or strikes, or a failure to procure adequate components, may lead to delays in manufacturing or increases in costs.

2026 filing excerpt – Risk Factors

The Company’s operations and financial results are subject to risks arising from evolving U.S.-China trade relations. Since a substantial portion of the Company’s products are manufactured by third-party contract manufacturers located in China, U.S. tariff policy on China-produced goods has remained a significant factor affecting the Company’s cost structure and supply chain decisions. Recent judicial decisions invalidating certain tariffs imposed under the International Emergency Economic Powers Act ("IEEPA") have increased uncertainty regarding the future direction of U.S. trade policy but have not eliminated the risk of increased import duties on products manufactured in China.

2025 filing excerpt – Business

It is unclear as to whether any emerging and evolving regulations will have a material impact on the Company’s results of operations. The Company did not engage any temporary personnel during the year ended June 30, 2025. None of our employees are covered by a collective bargaining agreement.

2026 filing excerpt – Business

The arrangements with foreign distributors do not contemplate that the Company pays any compensation other than any profit the distributors make upon their sale of the Company’s products. Diversification Strategy During the fiscal year ended June 30, 2026, management announced its intention to pursue acquisition targets as part of its “diversification by acquisition” strategy. The success of the Company’s intellectual property enforcement campaign, coupled with prudential cash management, has created an attractive opportunity to begin a new phase outside of the consumer electronics space.

REST EZ Inc.

Rank4
Lowest similarity sectionMD&A
Assessmentlow
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

REST EZ’s filing is mostly a refresh, with the biggest structural addition being a new cybersecurity disclosure section. The operating story is still the same: outsourced production, direct sales through wholesalers and retailers, and online distribution. The updated MD&A also reflects a new sales lead and another year of financing-dependent cash flow.

Main Changes

  • The filing adds a new Item 1C, "Cybersecurity," to the table of contents, indicating the company now includes a dedicated cybersecurity disclosure.
  • MD&A updates the named sales lead from "Mr. Sosa" to "Mr. Carson" and says direct sales will be conducted by Mr. Carson to wholesalers, retailers, and distributors worldwide.
  • The company’s cash flow disclosure is updated for the new year, showing cash provided by financing activities of $45,005 versus $104,987 in the prior year and no cash from investing activities.
  • The business description and strategy remain largely the same: outsourced manufacturing to Sport Energy, nationwide wholesale/retail/online distribution, and continued plans to expand the customer base.

Watch Items

  • The new cybersecurity section suggests management now sees cyber risk as material enough to disclose separately, which can matter for a small company with online sales.
  • The change in the named sales lead may signal a personnel shift in go-to-market execution, worth watching for continuity in customer relationships.
  • Financing cash inflows remain the main source of cash, so investors should watch whether the company can fund growth without repeated equity raises.

Important Filing Changes

2025 filing excerpt – MD&A

Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with: ● Our ability to raise capital necessary to sustain our anticipated operations and implement our business plan, ● Our ability to implement our business plan, ● Our ability to generate sufficient cash to pay our lenders and other creditors, ● Our ability to employ and retain qualified management and employees, ● Our dependence on the efforts and abilities of our current employees and executive officers, ● Changes in government regulations that are applicable to our current or anticipated business, ● Changes in the demand for our services and different food trends, ● The degree and nature of our competition, ● The lack of diversification of our business plan, ● The general volatility of the capital markets and the establishment of a market…

2026 filing excerpt – MD&A

Without limiting the generality of the foregoing, words such as “may”, “will”, “expect”, “believe”, “explore”, “consider”, “anticipate”, “intend”, “could”, “estimate”, “plan”, “propose” or “continue” or the negative variations of those words or comparable terminology are intended to identify forward-looking statements. Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with: ● Our CEO Mr. Carson is able to raise any amount of necessary cash needed sustain anticipated operations and implement our business plan, ● Our ability to implement our business plan, ● Our ability to generate sufficient cash to pay our lenders and other creditors, ● Our ability to employ and retain qualified management and employees, ● Our dependence on the efforts and abilities of our current employees and executive officers, ● Changes in government regulations that are applicable to our current or anticipated business, ● Changes in the demand for our services and different food trends, ● The degree and nature of our competition, ● The lack of diversification of our business plan, ● The general volatility of the capital markets and the establishment of a market for our shares, and ● Disruption in the economic and financial conditions primarily from the impact of past terrorist attacks in the United States, threats of future attacks, police and military activities overseas and other disruptive worldwide political and economic events, health pandemics and environmental weather conditions.

2025 filing excerpt – MD&A

Without limiting the generality of the foregoing, words such as “may”, “will”, “expect”, “believe”, “explore”, “consider”, “anticipate”, “intend”, “could”, “estimate”, “plan”, “propose” or “continue” or the negative variations of those words or comparable terminology are intended to identify forward-looking statements. Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with: ● Our ability to raise capital necessary to sustain our anticipated operations and implement our business plan, ● Our ability to implement our business plan, ● Our ability to generate sufficient cash to pay our lenders and other creditors, ● Our ability to employ and retain qualified management and employees, ● Our dependence on the efforts and abilities of our current employees and executive officers, ● Changes in government regulations that are applicable to our current or anticipated business, ● Changes in…

2026 filing excerpt – MD&A

Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with: ● Our CEO Mr. Carson is able to raise any amount of necessary cash needed sustain anticipated operations and implement our business plan, ● Our ability to implement our business plan, ● Our ability to generate sufficient cash to pay our lenders and other creditors, ● Our ability to employ and retain qualified management and employees, ● Our dependence on the efforts and abilities of our current employees and executive officers, ● Changes in government regulations that are applicable to our current or anticipated business, ● Changes in the demand for our services and different food trends, ● The degree and nature of our competition, ● The lack of diversification of our business plan, ● The general volatility of the capital markets and the establishment of a market for our shares, and ● Disruption in the economic and financial conditions primarily from the impact of past terrorist attacks in the United States, threats of future attacks, police and military activities overseas and other disruptive worldwide political and economic events, health pandemics and environmental weather conditions. We are also subject to other risks detailed from time to time in our other filings with the SEC and elsewhere in this report.

2025 filing excerpt – Risk Factors

However, a connection between high doses and these negative effects has not been proven. -Sleep Aid can also cause stomach pain, nausea, diarrhea, and muscle cramping if more than the recommended amount is taken. -There is some concern that combining sleeping aids with caffeine and the herb ephedra (also called Ma Huang) might increase the chance of having serious side effects such as nausea, or stomach pain. -There is concern that sleeping aids might cause irregular heartbeat in some people, but more information is needed to know if Sleep Aids can cause this problem. It is not known how the aforementioned side effects could impact our business. We suspect some potential users of the product may decide to forego purchase of the product, but such persons would not be within the target market of the product.

2026 filing excerpt – Risk Factors

However, the connection between high doses and these negative effects has not been proven. -Sleep Aid can also cause stomach pain, nausea, diarrhea, and muscle cramping if more than the recommended amount is taken. -There is some concern that combining sleeping aids with caffeine and the herb ephedra (also called Ma Huang) might increase the chance of having serious side effects such as nausea, or stomach pain. -There is concern that sleeping aids might cause irregular heartbeat in some people, but more information is needed to know if Sleep Aids can cause this problem. It is not known how the side effects could impact our business. We suspect some potential users of the product may decide to forgo purchase of the product, but such people would not be within the target market of the product.

JACK HENRY & ASSOCIATES INC

Rank5
Lowest similarity sectionMD&A
Assessmentlow
SEC filings2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text)

This filing is mostly a routine annual update, but it does add a clearer reference to faster payments within processing revenue. Management also updated its operating counts, showing slightly fewer clients and a small increase in associates, while sharpening the labor-cost risk language. Overall, the company still presents itself as a stable core banking and payments provider, with incremental emphasis on electronic payment services.

Main Changes

  • MD&A now compares "fiscal 2026 to fiscal 2025" instead of fiscal 2025 to fiscal 2024, with the prior-year comparison rolled forward.
  • The company says it serves "over 7,200" clients and "approximately 7,300" associates, versus "approximately 7,400" clients and "approximately 7,240" associates previously.
  • The revenue mix description adds "faster payments" to processing revenues, described as "electronic payment services," while the prior version did not name that category.
  • Risk factor wording tightens the labor shortage language to say competition for skilled associates, especially highly specialized technical personnel, has led to "wage inflation in the technology sector."

Watch Items

  • The new "faster payments" label suggests Jack Henry is emphasizing a growth area in payments, which could matter for product mix and revenue momentum.
  • The added wage inflation language points to continued pressure on hiring and retention costs in technical roles, a margin watch item.
  • The slight decline in stated client count versus the prior year may indicate modest churn or a narrower client base, worth monitoring against cross-sell and retention trends.

Important Filing Changes

2025 filing excerpt – MD&A

OVERVIEW Jack Henry & Associates, Inc. is a well-rounded financial technology company headquartered in Monett, Missouri, that employs approximately 7,240 full-time and part-time associates nationwide, and is a leading provider of technology solutions and payment processing services primarily to community and regional banks and credit unions. Our solutions serve approximately 7,400 clients and consist of integrated data processing systems solutions to banks ranging from de novo to multi-billion-dollar institutions with assets up to $55 billion, core data processing solutions for credit unions of all sizes, and non-core highly specialized core-agnostic products and services that enable banks and credit unions of every asset size and charter, and diverse corporate entities outside the financial services industry, to mitigate and control risks, optimize revenue and growth opportunities, and contain costs. Our integrated solutions are available for on-premise installation and delivery in our private…

2026 filing excerpt – MD&A

OVERVIEW Jack Henry & Associates, Inc. is a well-rounded financial technology company headquartered in Monett, Missouri, that employs approximately 7,300 full-time and part-time associates nationwide, and is a leading provider of technology solutions and payment processing services primarily to community and regional banks and credit unions. Our solutions serve over 7,200 clients and consist of integrated data processing systems solutions to banks ranging from de novo to multi-billion-dollar institutions with up to $55 billion in assets, core data processing solutions for credit unions of all sizes, and core-agnostic products and services that enable banks and credit unions of every asset size and charter, and diverse corporate entities outside the financial services industry, to mitigate and control risks, optimize revenue and growth opportunities, and contain costs. Our integrated solutions are available for on-premise installation and delivery in our private and public cloud.

2025 filing excerpt – MD&A

Our support infrastructure and strict standards provide service levels that generate high levels of client satisfaction and retention. We consistently measure client satisfaction using a variety of surveys, such as an annual survey on the client’s anniversary date and randomly-generated surveys initiated each day by routine support requests. Dedicated surveys are also used to grade specific aspects of our client experience, including product implementation, education, and consulting services.

2026 filing excerpt – MD&A

Our support infrastructure and strict standards provide service levels that generate high levels of client satisfaction and retention. We consistently measure and monitor client satisfaction using a variety of surveys, such as an annual survey on the client’s anniversary date and randomly-generated online surveys initiated each day by routine support requests to ensure feedback is received throughout the year. Dedicated surveys are also used to grade specific aspects of our client experience, including product implementation, education, and consulting services.

2025 filing excerpt – Risk Factors

The following is a description of some of the important risks and uncertainties that may cause our actual results of operations in future periods to differ materially from those expected or desired. Business and Operating Risks Data security breaches, failures, or other incidents could damage our reputation and business. Our business relies upon receiving, processing, storing, and transmitting sensitive information relating to our operations, associates, and clients.

2026 filing excerpt – Risk Factors

If we fail to maintain a sufficient digital security infrastructure, address security vulnerabilities and new threats, or deploy adequate technologies to secure our systems against attack, we may be subject to security breaches that compromise confidential information, including valuable intellectual property, proprietary information, trade secrets, know-how, or source code, which could lead to their theft, misuse, unauthorized disclosure, or misappropriation. Cybersecurity incidents, which, among other things, may result in unauthorized access to systems, service interruptions, malicious intrusions, exfiltration of data, ransomware, cyber-attacks, or operating failures, have become more sophisticated and more prevalent, have occurred in our systems in the past, and may occur in our systems in the future. Such incidents could adversely affect our ability to operate our business, damage our reputation and business, adversely affect our results of operations and financial condition, and expose us to liability.

Why SEC Filing Changes Matter

Research by Cohen et al. (Lazy Prices, 2020) — using the complete history of SEC filings from 1995 to 2014 — shows that when firms make active changes to their annual disclosures, those changes convey an important signal about future operations and returns. A portfolio that shorted "changers" and bought "non-changers" earned over 22% per year in annual alpha historically. Changes to the Risk Factors section, Business description, and language referring to the executive team were especially informative. Critically, these returns accrued gradually as information was later revealed through news and earnings — not at the time of filing — suggesting many investors remain inattentive to these simple, public signals. This snapshot is a starting point for deeper investigation, not a buy or sell recommendation.

For more like this, see the full SEC What Changed archive, browse more equity research reports, or subscribe to Quantitative Research Notes for new filing-change alerts as soon as they publish.

Get SEC filing alerts before prices move.

Material 10-K and 10-Q language changes, summarized the day they hit EDGAR.

No spam. Unsubscribe anytime.

Prefer Substack? Follow lf0 Research on Substack

Research disclaimer

This material is provided for research and educational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any security or strategy.

New stock analysis in your inbox.

Independent equity research on under-the-radar companies from lf0 — free, when new work publishes.




No spam. Unsubscribe anytime.

Prefer Substack? Follow lf0 Research on Substack

Leave a Comment

Your email address will not be published. Required fields are marked *